As compared to patients with AJCC stage and negative ADAMTS14 expression, the mortality hazard risk was multiplicatively enhanced among patients with lymph node metastasis (95% CI, 1.451–2.556; p < 0.001, HR = 1.9), advanced cancer stage (95% CI, 1.312–2.361; p < 0.001, HR = 1.8), and moderate/poor tumor differentiation (95%, 1.216–2.860, p = 0.004, HR = 1.9). This evidence concerns the gene ADAMTS14 and cancer.